Chardon Pharma more and more focuses on the use of zebrafish (Danio rerio) as experimental animals. The zebrafish has many traits that make it a valued complement to rodent disease models. Indeed, zebrafish have already been exploited in modeling both genetic and acquired human diseases, profiting from experimental approaches to which it is amenable. A particular strength of zebrafish models is the ability to examine the onset and progression of pathological processes in vivo and in real-time. Furthermore, zebrafish offer the possibility to screen potential drugs at a high-throughput and whole-animal level. An additional important advantage is the ease and cost efficiency of in-vivo drug tests.
Chardon Pharma has a strategic partnership with Noldus IT (Wageningen, The Netherlands) to develop new techniques for the performance of zebrafish studies.
Chardon Pharma operates in close cooperation with various clinical departments of the University Medical Center (UMC) and different academic research centers in Nijmegen like the Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour and the Psychology Laboratories. This cooperation means that access is available to the models which have been developed at these University Centers and that there are multiple options to initiate clinical research in new biomarkers and translational models.
In collaborations with partners, Chardon Pharma is involved in the development of IT solutions (e-health) for addiction disorders (gambling, drugs, alcohol and obesity).